© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
The current role of genomic testing in HR+ breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.
May 7th 2021
The goals of adjuvant therapy versus extended adjuvant therapy for early-stage HR+ breast cancer and current treatment options available for each approach.
Discussion of predictive and prognostic markers used to guide treatment decision-making in HR+ breast cancer.
Best practices for the appropriate and timely use of genomic assays in clinical practice for patients with HR+ breast cancer.
A review of NCCN-recommended genomic assays and their impact on the management of HR+ breast cancer.
Role of the Breast Cancer Index genomic index in therapeutic decision-making in the extended adjuvant setting in HR+ breast cancer.
Insights into ongoing unmet needs in the individualized management of HR+ breast cancer and thoughts regarding future directions.
The rationale for treating early-stage HR+ breast cancer with extended adjuvant therapy and factors that impact treatment selection.
A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.
Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.
Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.